Quick Answer
Harmony Biosciences Holdings, Inc. reported Long-Term Debt of $143.66 million for fiscal year 2025.
Harmony Biosciences Holdings, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $143.66M | -11.9% |
| 2024 | $163.02M | -8.7% |
| 2023 | $178.57M | -5.8% |
| 2022 | $189.65M | -0.2% |
| 2021 | $189.98M | -2.2% |
| 2020 | $194.25M | +98.3% |
| 2019 | $97.95M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $148.51M | -11.5% | -3.2% |
| June 30, 2025 | $153.34M | -10.5% | -3.1% |
| March 31, 2025 | $158.18M | -9.6% | -3.0% |
| December 31, 2024 | $163.02M | -8.7% | -2.9% |
| September 30, 2024 | $167.85M | -7.8% | -2.1% |
| June 30, 2024 | $171.42M | -5.0% | -2.0% |
| March 31, 2024 | $175.00M | -5.4% | -2.0% |
| December 31, 2023 | $178.57M | -5.8% | -2.0% |
- Harmony Biosciences Holdings, Inc. showed a decrease of -11.9% in Long-Term Debt compared to the prior fiscal year.
- Over the 2019–2025 period, Harmony Biosciences Holdings, Inc.’s long-term debt has grown by 46.7% (from $97.95 million to $143.66 million).
- The most recent figure is from Harmony Biosciences Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: